ALECENSARO Medication Recall Alert for Severe Hypertriglyceridemia Risk
Areazine synthesizes this Health Canada recall directly from Health Canada's official public data feed. See our methodology for full source attribution and refresh cadence.
Health Canada has issued a risk communication for ALECENSARO, warning of severe hypertriglyceridemia that can lead to acute pancreatitis in patients with lung cancer.
What this Health Canada recall tells you, and what most readers miss
This notice was issued by Health Canada on April 22, 2026 and geographically references Canada. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Product & Food Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, health-canada, medication.
What Happened
Hypertriglyceridemia, including severe and life-threatening events, has been identified as an adverse reaction associated with ALECENSARO (alectinib). This condition is a medical emergency as it may lead to acute pancreatitis.
Which Products Are Affected
The affected product is ALECENSARO, alectinib capsules, 150 mg. No specific model numbers, UPCs, quantities, or date ranges were provided in the source data.
What You Should Do
Healthcare professionals should counsel patients on the risks and benefits of ALECENSARO, measure blood triglyceride levels at baseline and periodically during treatment, monitor for signs of acute pancreatitis, and temporarily withhold the medication if severe hypertriglyceridemia or pancreatitis occurs until recovery.
Why This Matters
This risk communication underscores the potential for serious health complications in patients using ALECENSARO for lung cancer treatment, emphasizing the need for vigilant monitoring to prevent medical emergencies.
Source
Original source: Health Canada Official Notice ↗
Related Product & Food Recalls
All Product & Food Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this Health Canada recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,156 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to April 22, 2026.
Frequently Asked Questions
Common questions about this Health Canada recall.